ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

ACR Convergence 2020

November 5-9, 2020. All Virtual.

View by Number View by Title View Sessions
View by Date

Friday, November 6, 2020

9:00AM-11:00AM
Abstract Number: 0238
Gestational Desire and Certolizumab Pegol in Patients with Chronic Inflammatory Rheumatic Disease. Preliminary Results of the GESTAMAD Cohort
RA – Treatments Poster I: RA Treatments & Their Safety
9:00AM-11:00AM
Abstract Number: 0129
Glucocorticoid-Induced Osteoporosis in Patients with Chronic Inflammatory Rheumatic Diseases: A Multivariate Linear Regression Analysis Identifying Factors Affecting Bone Mineral Density
Osteoporosis & Metabolic Bone Disease Poster
9:00AM-11:00AM
Abstract Number: 0109
Glucocorticoid-Induced Osteoporosis: Are We Practicing Prevention?
Osteoporosis & Metabolic Bone Disease Poster
9:00AM-11:00AM
Abstract Number: 0259
Guillain-Barré Syndrome in Systemic Lupus Erythematosus – Results of a Nationwide Analysis
SLE – Diagnosis, Manifestations, & Outcomes Poster I: Clinical Manifestations
9:00AM-11:00AM
Abstract Number: 0332
Guselkumab Improved Work Productivity and Daily Activity in Patients with Psoriatic Arthritis: Results from a Phase 3 Trial
Spondyloarthritis Including Psoriatic Arthritis – Diagnosis, Manifestations, & Outcomes Poster I: Psoriatic Arthritis
9:00AM-11:00AM
Abstract Number: 0367
Guselkumab Induces Sustained Reduction in Acute Phase Proteins and Th17 Effector Cytokines in Active Psoriatic Arthritis in Two Phase-3 Clinical Trials (DISCOVER-1 and DISCOVER-2)
Spondyloarthritis Including Psoriatic Arthritis – Treatment Poster I
9:00AM-11:00AM
Abstract Number: 0370
Guselkumab-Treated Patients Achieved Clinically Meaningful Improvement in Systemic Symptoms as Measured with PROMIS Instrument: Results from Phase-3 Psoriatic Arthritis Trial DISCOVER 1
Spondyloarthritis Including Psoriatic Arthritis – Treatment Poster I
9:00AM-11:00AM
Abstract Number: 0045
Healthcare Practitioner Confidence Assessing Rashes in Patients of Skin of Color with Lupus
Healthcare Disparities in Rheumatology Poster
9:00AM-11:00AM
Abstract Number: 0328
Healthcare Utilization and Costs Among Patients with Psoriatic Arthritis and Psoriasis in the United States – a Retrospective Study of Claims Data from 2009 to 2020
Spondyloarthritis Including Psoriatic Arthritis – Diagnosis, Manifestations, & Outcomes Poster I: Psoriatic Arthritis
9:00AM-11:00AM
Abstract Number: 0329
Healthcare Utilization and Costs Associated with Functional Status in Patients with Psoriatic Arthritis
Spondyloarthritis Including Psoriatic Arthritis – Diagnosis, Manifestations, & Outcomes Poster I: Psoriatic Arthritis
9:00AM-11:00AM
Abstract Number: 0091
Helicobacter Pylori Infection, Autoimmune Disease and Paraproteinemia Influence the Presentation of a Cohort of 150 Pernicious Anemia Patients Diagnosed in a Rheumatology Clinic
Miscellaneous Rheumatic & Inflammatory Diseases Poster I: Diagnosis and Testing
9:00AM-11:00AM
Abstract Number: 0087
Hemophagocytic Syndrome. Clinical Characteristics and Prognostic Factors of a Series of 30 Clinical Cases
Miscellaneous Rheumatic & Inflammatory Diseases Poster I: Diagnosis and Testing
9:00AM-11:00AM
Abstract Number: 0190
Hepatic Steatosis in Rheumatoid Arthritis: Frequency and Disease-Related Contributors
RA – Diagnosis, Manifestations, & Outcomes Poster I: Multimorbidity
9:00AM-11:00AM
Abstract Number: 0316
High-sensitivity 18F-FDG PET/CT: A Diagnostic Tool for Psoriatic Arthritis
Spondyloarthritis Including Psoriatic Arthritis – Diagnosis, Manifestations, & Outcomes Poster I: Psoriatic Arthritis
9:00AM-11:00AM
Abstract Number: 0376
Higher Intake of Carbohydrates and Free Sugar Are Associated with Higher Disease Activity in Patients with Axial Spondyloarthritis
Spondyloarthritis Including Psoriatic Arthritis – Treatment Poster I
  • «Previous Page
  • 1
  • …
  • 11
  • 12
  • 13
  • 14
  • 15
  • …
  • 35
  • Next Page»
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology